WO2001005333A1 - Foam-type vascular prosthesis with well-defined angio-permissive open porosity - Google Patents
Foam-type vascular prosthesis with well-defined angio-permissive open porosity Download PDFInfo
- Publication number
- WO2001005333A1 WO2001005333A1 PCT/US1999/027629 US9927629W WO0105333A1 WO 2001005333 A1 WO2001005333 A1 WO 2001005333A1 US 9927629 W US9927629 W US 9927629W WO 0105333 A1 WO0105333 A1 WO 0105333A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prosthesis
- graft material
- range
- graft
- filler
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
Definitions
- This invention is directed to a vascular prosthesis having a well-defined pore structure to allow uninterrupted ingrowth of connective tissue into the wall of the prosthesis. Furthermore, mechanical properties of the prosthesis are matched with mechanical properties of a host vessel, thereby overcoming problems of compliance mismatch. BACKGROUND OF THE INVENTION
- causative factors may include the thrombogenicity of the grafts or the hydraulic roughness of the surface, especially in crimped grafts.
- the pore size of commercial e-PTFE grafts has been increased. Due to the irregular structure of the pores (between the nodes and internodular fibers), the available ingrowth spaces rapidly narrow down to sub-arteriole dimensions.
- Various researchers have produced "foam type" grafts, and although compliance matching was achieved to some extent by some, the structures obtained by them have certain disadvantages that prohibit or inhibit the ingrowth of connective tissue. These disadvantages include closed external and/or internal surfaces, closed or semi-closed cell structures with little or no inter-pore communication, and irregularly shaped and sized pores due to irregular filler materials used in the processes.
- polyurethanes Because of their unique combination of physical, chemical and biocompatible properties, polyurethanes have been studied and used in medical devices for over thirty years. Enzymatic hydrolysis, auto-oxidation, mineralization, and biologically induced environmental stress cracking of polyester- and polyetherurethanes have led manufacturers of medical polyurethanes to develop more specialized formulations to prevent these occurrences. These new generation polyurethane elastomers are being increasingly accepted as the biomaterials of choice in most applications, especially those requiring compliance. It is not surprising, therefor, that many researchers have used various polyurethane compositions (and other elastomers) to produce vascular grafts.
- Salt casting, phase inversion, spraying, and replamineform techniques have been used to produce sponge-like structures containing ill-defined pores, while filament winding and electrostatic spinning result in the formation of filamentous or fibrous structures.
- researchers have been able to approximate the compliance of natural blood vessels by careful manipulation of the process variables. Nevertheless, the performance of these experimental grafts is generally unsatisfactory. This indicates that compliance matching alone does not result in the desired healing patterns.
- a vascular prosthesis industry for a vascular graft having a well-defined pore structure in its walls to allow uninterrupted ingrowth of connective tissue into the walls of the prosthesis, wherein the problems of compliance mismatch are overcome.
- the present invention is directed to a graft with a porous wall structure containing interconnecting, uniformly shaped pores (i.e. voids) having average diameters between 10 and 300 ⁇ m, more preferably 40-110 ⁇ m.
- the standard deviation of the diameters of the pores is typically less than 20 ⁇ m, more preferably less than 10 ⁇ m.
- the openings between the pores are typically in the order of 1-100 ⁇ m, more typically 20-50 ⁇ m, depending on the size of the pores.
- the pores (i.e. voids) in the structure have well-defined, preferably spherical shapes, and the sizes of the ingrowth spaces are readily optimized for uninterrupted tissue and vessel ingrowth.
- the problem of compliance mismatch encountered with conventional grafts is also addressed by matching mechanical properties of the graft with mechanical properties of a host vessel. These mechanical properties include smoothness, elasticity and structural integrity.
- a tube is fashioned from an elastomeric polymer, for example, by molding an admixture of polymer, solvent (for the polymer), and spherical, soluble microbeads of a desired diameter. Extraction of the beads and precipitation of the polymer renders a tubular structure containing well- defined pores (in the tube wall) suitable for use as a synthetic, small-diameter vascular graft prosthesis.
- a paste comprising a polymer solution, for example, and an extractable filler is prepared and either rolled onto a mandrel, deposited as layers onto a mandrel, or extruded through an annular orifice. The polymer is then precipitated and the filler is extracted.
- An alternative method for making the invention involves melt extrusion of a thermoplastic elastomer with blowing agents to create porosity.
- FIG. 1 is a perspective view of a unit cell structure of the invention
- Fig. 2 is a perspective view of a pentagonal dodecahedron
- Fig. 3 is a cross-sectional view of a pentagonal dodecahedron
- Fig. 4 is a graphical representation of continuous ingrowth diameter as a function of height of the dodecahedron of Fig. 3;
- Fig. 5 is a cross-sectional view of a cluster of pentagonal dodecahedrons
- Fig. 6 is a graphical representation of continuous ingrowth diameter as a function of a plane angle through the dodecahedron in Fig. 5;
- Fig. 7 is a schematic view of a casting device used in producing the vascular prosthesis of the invention.
- extractable filler means any polymeric or other filler material that is soluble and/or extractable by a solvent other than the solvent used for the graft material.
- the material is preferably spherical in shape with average diameters ranging in size from 10 to 300 micrometers, more preferably from 40 to 110 micrometers.
- the beads are fractionated according to size, for example by sieving so that the individual fractions have a narrow size distribution.
- One example would be beads with a diameter of 85 ⁇ 10 ⁇ m, where 85 indicates the average size and 10 ⁇ m indicates the standard deviation.
- suitable materials include protein beads, e.g. alginate, gelatin, carbohydrates (sugar, dextrose, etc.), inorganic and organic salts. Water soluble fillers are suitable when water is the precipitation solvent and the filler extractor.
- filler extraction solvent means any solvent capable of dissolving the extractable filler without adversely affecting the graft structure.
- water is a suitable filler extraction solvent for water soluble fillers.
- precipitation solvent means any solvent that is capable of precipitating the graft material from solution.
- the precipitation solvent and the graft material solvent are usually miscible in all proportions.
- suitable precipitation solvents include: water, ethanol, acetone, or combinations of any of these.
- the filler extraction solvent and the precipitation solvent may or may not be the same solvent.
- graft material means any polymeric or other material that can be dissolved in a suitable solvent and re-solidified after graft manufacture by air-drying, phase inversion, or combinations thereof.
- suitable graft materials include: thermoplastic elastomers including thermoplastic polyurethanes, e.g. Pellethane, Biomer type polyurethanes, Chronoflex, Hydrothane, Estane, Elast-Eon, Texin, Biomer, Surethane, Corethane, Carbothane, Techoflex, Tecothane and Biospan.
- a polyurethane developed by Medtronic and described in U.S. Patent No. 4,873,308 is an example of a suitable graft material.
- graft material solvent means any solvent capable of dissolving the graft material.
- suitable solvents for polyurethanes include: N-methyl pyrrolidone (NMP), N,N dimethyl diacetamide (DMAC), 1,4 dioxane, etc.
- graft material solution means a solution of the graft material in the graft material solvent in concentrations ranging from 1 to 40% by mass, more typically 5 to 30% by mass, usually 10 to 25% by mass.
- graft material paste means an admixture consisting of a graft material solution and an extractable filler.
- the ratio of filler to graft material in the solution can range from 20:1 to 1 :1, more typically from 10: 1 to 5:1 (ratios by mass).
- chemical blowing agent means any material that decomposes to form a gas, e.g. C0 2 or N 2 , wherein the gas creates pores in the graft material. Examples of chemical blowing agents include bicarbonates, N- nitroso compounds, azides, azodicarbonamides, and a variety of other agents.
- physical blowing agent means either a liquid or a gas that is introduced to molten graft material under pressure, wherein evaporation of the liquid or expansion of the gas creates bubbles that form pores in the graft material.
- physical blowing agents include: chloro-fluoro carbons (e.g. freon), pentane, and hexane.
- An improved prosthetic vascular graft can be created with a synthetic scaffold of transmural ingrowth channels which are characterized by a continuous, uninterrupted, well-defined dimension.
- a simulated cell structure with unit cells approximating pentagonal dodecahedrons allows such channels to be formed.
- a unit cell created in a foam type structure can be, and often is, represented by an idealized pentagonal dodecahedron.
- a process for producing such well-defined pores (i.e. voids) in a synthetic scaffold can be achieved using spherical, soluble microbeads as an extractable filler. The process is explained in detail below.
- Fig. 1 shows a typical unit cell 10 created in a foam type structure.
- Fig. 2 shows a pentagonal dodecahedron 12.
- a simulated unit cell 10 achieved in the present invention resembles the pentagonal dodecahedron 12, but may vary in the number of sides or the simulated unit cell 10 may be somewhat oblong.
- a structure containing such multi-sided unit cells in a very narrow size range is well-defined, and sizes of ingrowth channels are readily calculated.
- Fig. 3 shows two different possible direct routes which may be used as ingrowth channels in a pentagonal dodecahedron.
- Direct Route 1 enters the cell at an angle perpendicular to a face of the cell.
- Direct Route 2 enters the cell at an angle non-perpendicular to a face of the cell.
- Fig. 4 is a graphical representation of a correlation between a continuous ingrowth diameter (D) of each of the two routes in Fig. 3 as a function of the dodecahedron's height (H) in Fig. 3. As can be seen in Fig.
- the continuous ingrowth diameter increases more rapidly for routes entering the cell at an angle perpendicular to a face of the cell than for routes entering the cell at an angle non-perpendicular to a face of the cell. Whether the angle of entry is perpendicular or not, the cells provide ample ingrowth channels of continuous, uninterrupted, well-defined dimensions.
- Fig. 5 shows a structure 14 including a cluster of pentagonal dodecahedrons with a possible route indicated, along with an illustrated plane angle ( ⁇ ) measured against a line running through the cluster of dodecahedrons perpendicular to the face of the dodecahedron at which it enters.
- Fig. 6 is a graphical representation of a diameter of a path through the well-defined dodecahedron structure as the plane angle is altered for various bead sizes: 30, 60 and 100 microns. As can be seen in Fig. 6, when the plane angle is 0°, the diameter of a continuous pore is slightly larger than half the diameter of the bead. Thus, there is quite a large area in which continuous ingrowth of connective tissue can occur.
- the well-defined porosity is oriented in such a way as to allow for circumferential and longitudinal orientation from radial ingrowth.
- mechanical properties of the graft especially smoothness, elasticity and structural integrity
- mechanical properties of the host vessel thereby overcoming problems of compliance mismatch.
- An intima which includes an endothelium attached to a basement membrane, provides a non-thrombogenic blood contacting surface.
- a media contains smooth muscle cells (SMC's) as well as elastic and other intercellular connective and matrix materials, and supplies two other important properties to the blood vessel, namely compliance and contractility.
- SMC's smooth muscle cells
- the tissues are oriented in a helical fashion in this medial layer.
- Another important property, namely structural integrity, is provided by an adventitia.
- the configuration of collagen fibers in this layer provides for "stiffening" of the vessel when subjected to high internal pressures, i.e. a decrease in compliance with increased strain.
- material for the scaffold should have biostability, processability, availability, and desirable mechanical properties.
- the porous scaffold should provide high porosity for maximal cell ingrowth and minimal bulk compressibility (to allow for compressibility associated with contractility).
- the prosthesis should have structural integrity and viscoelastic properties similar to those observed for natural vessels.
- the scaffold should also exhibit long-term in- vivo stability.
- suitable scaffold materials include thermoplastic elastomers, particularly thermoplastic polyurethanes.
- the well-defined porosity should be oriented in such a way as to allow for circumferential and longitudinal orientation from radial ingrowth to allow physiological contractility. Such orientation is provided by the pentagonal dodecahedron, as illustrated in Figs. 3-6. Furthermore, the prosthesis must have structural integrity and viscoelastic properties similar to those observed for natural vessels.
- a suitable filler material to create the pores requires careful consideration.
- the material should be: non-soluble in the solvent used to dissolve the scaffold material; readily soluble in the precipitation solution or other non-solvent for the scaffold material; crush resistant to withstand mixing and forming of pastes; and non- toxic.
- Fractionated salt crystals NaHC0 3 , and others
- their aspect ratios and fairly wide size distributions make them less than ideal candidates for use in the production of foamed structures.
- Spherical, soluble microbeads can be manufactured to narrow tolerances. The use of these spherical beads contributes to the production of porous "foam" scaffolds that are much better defined than those obtainable from salt crystals.
- the extractable filler comprises uniformly shaped particles, preferably spherical in shape.
- the average diameters of the particles, as well as the resulting pores range in size from 10 to 300 micrometers, more preferably from 40 to 110 micrometers.
- the standard deviation of the particle diameters and corresponding pore sizes are preferably within a controlled range of 20 ⁇ m of one another, more preferably within 10 ⁇ m of one another. In an embodiment wherein the particles and pores are not spherical but are uniformly shaped, the particles and pores can still be maintained in a controlled range of volume.
- non-spherical particles and pores that are uniformly shaped can have volumes maintained in a controlled range where the standard f ' ⁇ deviation will be less than 4.2 x 10 " mm .
- the most preferred method for producing the grafts of the present invention is a vacuum impregnation technique. Referring to Fig. 7, this method involves assembling a mandrel 18 in a custom-designed casting device 16.
- the casting device includes a top manifold 20 that allows for application of air pressure 22 to a top portion of a mold or molds 24.
- a bottom manifold 26 of the device allows for application of a vacuum 28 to a bottom portion of the mold or molds 24. Any number of the molds 24 is clamped between the top and bottom manifolds 20 and 26.
- molds 24 are cylindrical tubes made of glass or other suitable materials with an inside diameter corresponding to a desired outside diameter of a resulting graft.
- the molds 24 are used in conjunction with cylindrical central rods 18.
- the cylindrical central rods 18 are made of stainless steel, glass or other suitable materials with an outside diameter corresponding to a desired inner diameter of a resulting graft.
- a reservoir 30 for graft material solution and a centralizing spacer 32 is also used in conjunction with the molds 24.
- the grafts are formed by filling an annular space 34 between the central rod 18 and the tube 24 with an extractable filler.
- Suitable filler materials include alginate, gelatin, carbohydrates, inorganic and organic salts.
- the reservoir 30 is filled with a graft material solution comprising graft material in a graft material solvent.
- Suitable graft materials include thermoplastic elastomers including thermoplastic polyurethanes, such as Pellethane, Biomer type polyurethanes, Chronoflex and Hydrothane. In particular, a polyurethane developed by
- Suitable graft material solvents include N-methyl pyrrolidone (NMP), N,N dimethyl diacetamide (DMAC), 1,4 dioxane, etc. Concentration of the graft material in the graft material solvent ranges from 1 to 40% by mass, more typically 5 to 30% by mass, usually 10 to 25% by mass.
- the concentration depends on various factors, including composition of the graft material, composition of the graft material solvent, and viscosity of the solution.
- the top manifold 20 is then closed and pressure 22 is applied to the top manifold 20 and/or vacuum 28 is applied to the bottom manifold 26 to force the graft material solution into interstices between the packed extractable filler.
- the amount of pressure should be on the order of about atmospheric to 15 bar, more preferably 5 to 8 bar.
- the amount of vacuum should be on the order of about atmospheric to -1 bar, more typically about -0.9 bar.
- the tube 24, graft and rod 18 are removed from the device 16.
- Precipitation of the graft (defined as removal of the graft material solvent) is begun with immersion into precipitation solvent. Suitable precipitation solvents include water, ethanol, acetone, or combinations of any of these.
- the central rod 18 is then removed from the graft and the tube 24.
- Precipitation of the graft material and extraction of the graft material solvent are completed by extended immersion in the precipitation solvent.
- the precipitated graft is removed from the tube 24.
- the extractable filler is extracted from the precipitated graft material to produce the porous structure of the invention.
- the filler can be extracted using a filler extraction solvent, such as water. The precipitation and extraction may be effected either simultaneously or consecutively.
- Another method for producing the porous structure of the invention is a paste molding technique.
- a paste is prepared from an extractable filler and a graft material solution including graft material and graft material solvent, as described above.
- the paste contains the filler and the graft material in a ratio of mass between 20: 1 and 1 : 1, respectively. More typically the ratio is between 10: 1 and 5: 1.
- a desired thickness of paste is rolled onto a mandrel, wherein the mandrel has an outer diameter equal to a desired internal diameter of a resulting graft.
- the internal diameter of the graft is preferably between 1 mm and 20 mm, more preferably in the range of 2 to 6 mm for small diameter vessel replacement.
- the thickness of the paste can vary from 0.1 to 5 mm, more preferably from 0.4 to 1.5 mm, depending on the diameter of the graft.
- the graft material solution is then precipitated by immersion in precipitation solvent, and the filler is extracted by immersion in a filler extraction solvent, as described above.
- the precipitation and extraction may be effected either simultaneously or consecutively.
- a paste extrusion technique is a paste extrusion technique.
- a paste is prepared from an extractable filler and a graft material solution comprising graft material and graft material solvent, as described above.
- the paste is extruded through an annular orifice.
- the graft material solution is then precipitated by immersion in precipitation solvent, and the filler is extracted by immersion in filler extraction solvent.
- the precipitation and extraction may be effected either simultaneously or consecutively.
- a further method for producing the porous structure of the invention is a dip coating technique.
- a paste is prepared (as described above) from an extractable filler and a graft material solution including graft material and graft material solvent.
- the paste is deposited in consecutive layers onto a mandrel.
- the graft material solution is then precipitated by immersion in precipitation solvent, and the filler is extracted by immersion in filler extraction solvent.
- the precipitation and extraction may be effected either simultaneously or consecutively.
- thermoplastic elastomer is extruded with the use of physical and/or chemical blowing agents to produce a foamed graft.
- Suitable thermoplastic elastomers include thermoplastic polyurethanes, such as Pellethane, Biomer type polyurethanes, Chronoflex, and Hydrothane.
- Suitable chemical blowing agents include sodium bicarbonate and azodicarbonamides.
- Suitable physical blowing agents include chloro-fluoro carbons (e.g. freon), pentane, and hexane.
- the foamed graft is then annealed and reticulated, where needed, to effect an open-cell structure.
- a third method is another mechanical method wherein explosive gasses (e.g. stoichiometric ratios of 0 2 /H 2 ) are infiltrated into the pores.
- the cells are ruptured by ignition of these gasses.
- Yet another method is a chemical method whereby the foam is subjected to hydrolysis, thereby destroying the thinner membranes more rapidly than the thicker ribs defining the pores. Any of these methods can be used alone or in combination to produce open cell foams.
- a final method of producing the graft involved the use of a process whereby the foamed tube is formed by the reaction of monomeric substances
- reaction injection molding or RIM process reaction injection molding or RIM process
- suitable blowing agents e.g. water
- Reinforcing fibers can be incorporated into the graft design in any of the described methods to alleviate this problem.
- the reinforcing fibers can be incorporated into the grafts by winding the fibers around the scaffold while the graft material is in a paste or solution form, for example.
- Suitable fibers include either elastic or non-elastic non-degradable material, or a combination of elastic and non-elastic materials.
- a reinforcing material that is either elastic or non-elastic, and is degradable in vivo, can be used in combination with the non-degradable material to provide initial strength to the graft.
- the reinforcement material that is degradable in vivo degrades as the graft is populated by ingrowing cells and accompanying extracellular matrix material. Ingrowing material tends to stiffen the graft; therefore, a degradable fiber can be used to give initial strength to the graft without making the graft overly stiff after ingrowth.
- the non-extractable fiber typically has a diameter ranging in size from 10 to 100 micrometers.
- non-elastic, non-degradable materials include polyethylene terephthalate (PET, Dacron) and polytetrafluoroethylene (PTFE).
- suitable elastic non-degradable materials include thermoplastic polyurethanes, e.g. M48, Pellethane (or clones), Biomer (or clones), or any other biocompatible elastomer. Degradable polyurethanes can serve as degradable reinforcing fibers.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU16313/00A AU1631300A (en) | 1999-07-20 | 1999-11-19 | Foam-type vascular prosthesis with well-defined angio-permissive open porosity |
DE69931401T DE69931401T2 (en) | 1999-07-20 | 1999-11-19 | FOAMED PROSTHESIS WITH WELL-DEFINED ANGIO-PERMISSIVE OPEN PORO-SITY |
EP99959063A EP1202683B1 (en) | 1999-07-20 | 1999-11-19 | Foam-type vascular prosthesis with well-defined angio-permissive open porosity |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14470499P | 1999-07-20 | 1999-07-20 | |
US60/144,704 | 1999-07-20 | ||
US09/434,649 US6702848B1 (en) | 1999-07-20 | 1999-11-05 | Foam-type vascular prosthesis with well-defined anclio-permissive open porosity |
US09/434,649 | 1999-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001005333A1 true WO2001005333A1 (en) | 2001-01-25 |
Family
ID=26842277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/027629 WO2001005333A1 (en) | 1999-07-20 | 1999-11-19 | Foam-type vascular prosthesis with well-defined angio-permissive open porosity |
Country Status (5)
Country | Link |
---|---|
US (3) | US6702848B1 (en) |
EP (1) | EP1202683B1 (en) |
AU (1) | AU1631300A (en) |
DE (1) | DE69931401T2 (en) |
WO (1) | WO2001005333A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003015837A1 (en) * | 2001-08-17 | 2003-02-27 | Medtronic, Inc. | Porous vascular graft prostheses with luminal sealing layer |
EP1670385A2 (en) * | 2003-10-01 | 2006-06-21 | University of Washington | Novel porous biomaterials |
EP1727498A2 (en) * | 2004-01-23 | 2006-12-06 | The Biometrix Corporation | Endovascular treatment devices and methods |
WO2009047346A1 (en) * | 2007-10-11 | 2009-04-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for preparing porous scaffold for tissue engineering, cell culture and cell delivery |
US8501913B2 (en) | 2009-10-02 | 2013-08-06 | Vib Vzw | Spider mite silk proteins |
JP2016174538A (en) * | 2015-03-18 | 2016-10-06 | 富士フイルム株式会社 | Tubular structure, method for producing cell structure, and method for producing tubular structure |
CN107106727A (en) * | 2014-10-31 | 2017-08-29 | 富士胶片株式会社 | The manufacture method of tubular structure thing, the device for manufacturing tubular structure thing and tubular structure thing |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6585752B2 (en) * | 1998-06-23 | 2003-07-01 | Innercool Therapies, Inc. | Fever regulation method and apparatus |
US6540780B1 (en) * | 1998-11-23 | 2003-04-01 | Medtronic, Inc. | Porous synthetic vascular grafts with oriented ingrowth channels |
DE60115712T2 (en) | 2000-08-23 | 2006-09-07 | Thoratec Corp., Pleasanton | COATED TUBE TRANSPLANTS AND USE METHOD |
US8038708B2 (en) * | 2001-02-05 | 2011-10-18 | Cook Medical Technologies Llc | Implantable device with remodelable material and covering material |
US20030176516A1 (en) * | 2002-03-15 | 2003-09-18 | Greene, Tweed Of Delaware, Inc. | Cellular perfluoroelastomeric compositions, sealing members, methods of making the same and cellular materials for medical applications |
US20050222688A1 (en) * | 2002-05-10 | 2005-10-06 | Medtronic, Inc. | Transmural concentric multilayer ingrowth matrix within well-defined porosity |
US7550004B2 (en) * | 2002-08-20 | 2009-06-23 | Cook Biotech Incorporated | Endoluminal device with extracellular matrix material and methods |
CA2448592C (en) | 2002-11-08 | 2011-01-11 | Howmedica Osteonics Corp. | Laser-produced porous surface |
US20060147332A1 (en) | 2004-12-30 | 2006-07-06 | Howmedica Osteonics Corp. | Laser-produced porous structure |
AU2003902037A0 (en) * | 2003-04-24 | 2003-05-15 | Mclachlan, Craig | Method for tissue growth |
BRPI0410324A (en) | 2003-05-15 | 2006-05-23 | Biomerix Corp | implantable device, elastomeric matrix production lyophilization processes having a cross-linked structure, polymerization for cross-linked elastomeric matrix preparation and cross-linked composite elastomeric implant preparation, and method for treating an orthopedic disorder |
US20050055085A1 (en) * | 2003-09-04 | 2005-03-10 | Rivron Nicolas C. | Implantable medical devices having recesses |
EP1691854B1 (en) * | 2003-11-03 | 2011-09-14 | Medtronic, Inc. | Hydrogel providing cell-specific ingrowth |
US7763077B2 (en) | 2003-12-24 | 2010-07-27 | Biomerix Corporation | Repair of spinal annular defects and annulo-nucleoplasty regeneration |
DE102005003188A1 (en) * | 2005-01-20 | 2006-07-27 | Restate Patent Ag | Medical implant made of an amorphous or nanocrystalline alloy |
US7469437B2 (en) | 2005-06-24 | 2008-12-30 | Tempur-Pedic Management, Inc. | Reticulated material body support and method |
WO2007016251A2 (en) * | 2005-07-28 | 2007-02-08 | Cook Incorporated | Implantable thromboresistant valve |
US8728387B2 (en) | 2005-12-06 | 2014-05-20 | Howmedica Osteonics Corp. | Laser-produced porous surface |
US8211168B2 (en) * | 2006-02-21 | 2012-07-03 | Cook Biotech Incorporated | Graft material, stent graft and method |
WO2008076383A2 (en) * | 2006-12-18 | 2008-06-26 | Med Institute Inc. | Stent graft with releasable therapeutic agent |
US20100196439A1 (en) * | 2006-12-22 | 2010-08-05 | Medtronic, Inc. | Angiogenesis Mechanism and Method, and Implantable Device |
US20100070020A1 (en) * | 2008-06-11 | 2010-03-18 | Nanovasc, Inc. | Implantable Medical Device |
US8956475B2 (en) | 2007-12-11 | 2015-02-17 | Howard Riina | Method and apparatus for restricting flow through an opening in the side wall of a body lumen, and/or for reinforcing a weakness in the side wall of a body lumen, while still maintaining substantially normal flow through the body lumen |
EP2227193B8 (en) * | 2007-12-11 | 2022-09-07 | Cornell University | Apparatus for sealing an opening in the side wall of a body lumen |
WO2010085344A1 (en) | 2009-01-22 | 2010-07-29 | Cornell University | Method and apparatus for restricting flow through the wall of a lumen |
DE102009047925A1 (en) * | 2009-10-01 | 2011-06-16 | Qualimed Innovative Medizinprodukte Gmbh | Endoluminal tubular stent graft |
CN103037911B (en) | 2010-04-08 | 2015-07-15 | 矽瑞奥科技公司 | Implantable medical devices having microporous surface layers and method for reducing foreign body response to the same |
EP2517619B1 (en) | 2011-04-27 | 2013-05-22 | Istar Medical | Improvements in or relating to glaucoma management and treatment |
US9381112B1 (en) | 2011-10-06 | 2016-07-05 | William Eric Sponsell | Bleb drainage device, ophthalmological product and methods |
WO2013055703A1 (en) | 2011-10-07 | 2013-04-18 | Cornell University | Method and apparatus for restricting flow through an opening in a body lumen while maintaining normal flow |
US8632489B1 (en) | 2011-12-22 | 2014-01-21 | A. Mateen Ahmed | Implantable medical assembly and methods |
WO2014049817A1 (en) * | 2012-09-28 | 2014-04-03 | テルモ株式会社 | Medical member |
CN107809977B (en) | 2015-06-24 | 2021-04-09 | 希里奥尼克斯公司 | Injectable porous device for the treatment of dry and wet age-related macular degeneration or diabetic retinopathy |
JP7114020B2 (en) * | 2016-01-09 | 2022-08-08 | ステンティト ビー.ブイ. | Fiber tubular conduit for stenting |
US11268213B2 (en) | 2016-10-10 | 2022-03-08 | Heedae Park | Core-free thermoplastic polyurethane yarn with added nanosilica |
KR101879981B1 (en) * | 2016-10-10 | 2018-07-19 | 박희대 | method for manufcturing thermoplastic polyurethane yarn |
US20210369912A1 (en) * | 2018-05-07 | 2021-12-02 | Mentor Worldwide Llc | 2d and 3d bioscaffold extracellular structural unit and tissue structure design and methods of manufacture |
WO2023195039A1 (en) * | 2022-04-04 | 2023-10-12 | テルモ株式会社 | Indwelling medical object |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4459252A (en) * | 1975-05-09 | 1984-07-10 | Macgregor David C | Method of forming a small bore flexible vascular graft involving eluting solvent-elutable particles from a polymeric tubular article |
US4657544A (en) * | 1984-04-18 | 1987-04-14 | Cordis Corporation | Cardiovascular graft and method of forming same |
US4725273A (en) * | 1985-08-23 | 1988-02-16 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Artificial vessel having excellent patency |
EP0286220A1 (en) * | 1987-04-09 | 1988-10-12 | Newtec Vascular Products Ltd. | Methods and apparatus for making polymer material |
EP0315814A2 (en) * | 1987-10-23 | 1989-05-17 | Dow Corning Corporation | Methods for forming porous-surfaced polymeric bodies |
US4834746A (en) * | 1983-06-06 | 1989-05-30 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Artificial vessel and process for preparing the same |
EP0332371A1 (en) * | 1988-03-07 | 1989-09-13 | Dow Corning Wright Corporation | Method for forming hollow, porous-surfaced elastomeric bodies |
US4932964A (en) * | 1987-12-07 | 1990-06-12 | Sulzer Brothers Limited | Artificial body for a prosthesis |
WO1990006094A1 (en) * | 1988-12-08 | 1990-06-14 | Brigham And Women's Hospital | Prosthesis of foam and collagen |
WO1992009652A1 (en) * | 1990-11-22 | 1992-06-11 | Newtec V.P. Limited | Polymer products |
US5549664A (en) * | 1990-07-31 | 1996-08-27 | Ube Industries, Ltd. | Artificial blood vessel |
US5628781A (en) * | 1985-06-06 | 1997-05-13 | Thomas Jefferson University | Implant materials, methods of treating the surface of implants with microvascular endothelial cells, and the treated implants themselves |
EP0815806A2 (en) * | 1996-06-27 | 1998-01-07 | Cordis Corporation | Controlled porosity endovascular implant |
RU2136435C1 (en) * | 1998-09-08 | 1999-09-10 | Институт машиноведения и металлургии ДВО РАН | Method of production of continuously cast deformed hollow castings and device for its embodiment |
US6056993A (en) * | 1997-05-30 | 2000-05-02 | Schneider (Usa) Inc. | Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4286341A (en) * | 1979-04-16 | 1981-09-01 | Iowa State University Research Foundation, Inc. | Vascular prosthesis and method of making the same |
US4441215A (en) | 1980-11-17 | 1984-04-10 | Kaster Robert L | Vascular graft |
GB2121286B (en) | 1982-06-02 | 1985-11-06 | Ethicon Inc | Improvements in synthetic vascular grafts, and methods of manufacturing such grafts |
DE3478192D1 (en) | 1983-06-06 | 1989-06-22 | Kanegafuchi Chemical Ind | Artificial vessel and process for preparing the same |
US5108424A (en) | 1984-01-30 | 1992-04-28 | Meadox Medicals, Inc. | Collagen-impregnated dacron graft |
US5197977A (en) | 1984-01-30 | 1993-03-30 | Meadox Medicals, Inc. | Drug delivery collagen-impregnated synthetic vascular graft |
US4842575A (en) | 1984-01-30 | 1989-06-27 | Meadox Medicals, Inc. | Method for forming impregnated synthetic vascular grafts |
US4605406A (en) | 1984-08-03 | 1986-08-12 | Medtronic, Inc. | Method for fabricating prosthesis material |
US5037377A (en) | 1984-11-28 | 1991-08-06 | Medtronic, Inc. | Means for improving biocompatibility of implants, particularly of vascular grafts |
US4743252A (en) | 1986-01-13 | 1988-05-10 | Corvita Corporation | Composite grafts |
DE3608158A1 (en) | 1986-03-12 | 1987-09-17 | Braun Melsungen Ag | VESSELED PROSTHESIS IMPREGNATED WITH CROSSLINED GELATINE AND METHOD FOR THE PRODUCTION THEREOF |
JPH0696023B2 (en) | 1986-11-10 | 1994-11-30 | 宇部日東化成株式会社 | Artificial blood vessel and method for producing the same |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5024671A (en) | 1988-09-19 | 1991-06-18 | Baxter International Inc. | Microporous vascular graft |
US4873308A (en) | 1988-09-30 | 1989-10-10 | Medtronic, Inc. | Biostable, segmented aliphatic polyurethanes and process therefor |
KR920000459B1 (en) | 1989-12-13 | 1992-01-14 | 재단법인 한국화학연구소 | Artificial vascular tube |
US5584875A (en) | 1991-12-20 | 1996-12-17 | C. R. Bard, Inc. | Method for making vascular grafts |
US5282861A (en) | 1992-03-11 | 1994-02-01 | Ultramet | Open cell tantalum structures for cancellous bone implants and cell and tissue receptors |
DE69325649T2 (en) * | 1992-03-13 | 1999-11-18 | Atrium Medical Corp | OBJECTS OF EXPANDED FLUOROPOLYMER (e.g. POLYTETRAFLUORETHYLENE) WITH CONTROLLED POROSITY AND ITS PRODUCTION |
EP0566245B1 (en) * | 1992-03-19 | 1999-10-06 | Medtronic, Inc. | Intraluminal stent |
US5314925A (en) * | 1992-12-03 | 1994-05-24 | General Electric Company | Use of polytetrafluoroethylene resins as a nucleating agent for foam molded thermoplastics |
US5807406A (en) | 1994-10-07 | 1998-09-15 | Baxter International Inc. | Porous microfabricated polymer membrane structures |
US5709934A (en) | 1994-11-22 | 1998-01-20 | Tissue Engineering, Inc. | Bipolymer foams having extracellular matrix particulates |
US5891558A (en) * | 1994-11-22 | 1999-04-06 | Tissue Engineering, Inc. | Biopolymer foams for use in tissue repair and reconstruction |
ATE257001T1 (en) | 1995-10-25 | 2004-01-15 | Sm Technologies Llc | METHOD FOR PRODUCING AN OBJECT FROM POROUS MATERIAL |
US6143037A (en) | 1996-06-12 | 2000-11-07 | The Regents Of The University Of Michigan | Compositions and methods for coating medical devices |
CA2308396A1 (en) * | 1997-05-14 | 1998-11-19 | Novo Rps Ulc | Expandable stent and method for production of same |
US6177522B1 (en) * | 1997-11-07 | 2001-01-23 | Salviac Limited | Biostable polycarbonate urethane products |
US6554857B1 (en) * | 1999-07-20 | 2003-04-29 | Medtronic, Inc | Transmural concentric multilayer ingrowth matrix within well-defined porosity |
US6702849B1 (en) * | 1999-12-13 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers |
-
1999
- 1999-11-05 US US09/434,649 patent/US6702848B1/en not_active Expired - Fee Related
- 1999-11-19 WO PCT/US1999/027629 patent/WO2001005333A1/en active IP Right Grant
- 1999-11-19 DE DE69931401T patent/DE69931401T2/en not_active Expired - Lifetime
- 1999-11-19 AU AU16313/00A patent/AU1631300A/en not_active Abandoned
- 1999-11-19 EP EP99959063A patent/EP1202683B1/en not_active Expired - Lifetime
-
2001
- 2001-01-09 US US09/757,527 patent/US6616699B2/en not_active Expired - Fee Related
-
2003
- 2003-07-02 US US10/612,082 patent/US7632306B2/en not_active Expired - Fee Related
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4459252A (en) * | 1975-05-09 | 1984-07-10 | Macgregor David C | Method of forming a small bore flexible vascular graft involving eluting solvent-elutable particles from a polymeric tubular article |
US4834746A (en) * | 1983-06-06 | 1989-05-30 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Artificial vessel and process for preparing the same |
US4657544A (en) * | 1984-04-18 | 1987-04-14 | Cordis Corporation | Cardiovascular graft and method of forming same |
US5628781A (en) * | 1985-06-06 | 1997-05-13 | Thomas Jefferson University | Implant materials, methods of treating the surface of implants with microvascular endothelial cells, and the treated implants themselves |
US4725273A (en) * | 1985-08-23 | 1988-02-16 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Artificial vessel having excellent patency |
EP0286220A1 (en) * | 1987-04-09 | 1988-10-12 | Newtec Vascular Products Ltd. | Methods and apparatus for making polymer material |
EP0315814A2 (en) * | 1987-10-23 | 1989-05-17 | Dow Corning Corporation | Methods for forming porous-surfaced polymeric bodies |
US4932964A (en) * | 1987-12-07 | 1990-06-12 | Sulzer Brothers Limited | Artificial body for a prosthesis |
EP0332371A1 (en) * | 1988-03-07 | 1989-09-13 | Dow Corning Wright Corporation | Method for forming hollow, porous-surfaced elastomeric bodies |
WO1990006094A1 (en) * | 1988-12-08 | 1990-06-14 | Brigham And Women's Hospital | Prosthesis of foam and collagen |
US5549664A (en) * | 1990-07-31 | 1996-08-27 | Ube Industries, Ltd. | Artificial blood vessel |
WO1992009652A1 (en) * | 1990-11-22 | 1992-06-11 | Newtec V.P. Limited | Polymer products |
EP0815806A2 (en) * | 1996-06-27 | 1998-01-07 | Cordis Corporation | Controlled porosity endovascular implant |
US6056993A (en) * | 1997-05-30 | 2000-05-02 | Schneider (Usa) Inc. | Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel |
RU2136435C1 (en) * | 1998-09-08 | 1999-09-10 | Институт машиноведения и металлургии ДВО РАН | Method of production of continuously cast deformed hollow castings and device for its embodiment |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Section Ch Week 200035, Derwent World Patents Index; Class M22, AN 2000-409465, XP002901177 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003015837A1 (en) * | 2001-08-17 | 2003-02-27 | Medtronic, Inc. | Porous vascular graft prostheses with luminal sealing layer |
US8318193B2 (en) | 2003-10-01 | 2012-11-27 | University Of Washington | Crosslinked porous biomaterials |
EP1670385A2 (en) * | 2003-10-01 | 2006-06-21 | University of Washington | Novel porous biomaterials |
EP1670385A4 (en) * | 2003-10-01 | 2009-11-18 | Univ Washington | Novel porous biomaterials |
US7972628B2 (en) | 2003-10-01 | 2011-07-05 | University Of Washington | Porous biomaterials |
EP1727498A2 (en) * | 2004-01-23 | 2006-12-06 | The Biometrix Corporation | Endovascular treatment devices and methods |
EP1727498A4 (en) * | 2004-01-23 | 2009-12-16 | Biomerix Corp | Endovascular treatment devices and methods |
WO2009047346A1 (en) * | 2007-10-11 | 2009-04-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for preparing porous scaffold for tissue engineering, cell culture and cell delivery |
US9522218B2 (en) | 2007-10-11 | 2016-12-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for preparing porous scaffold for tissue engineering, cell culture and cell delivery |
US8501913B2 (en) | 2009-10-02 | 2013-08-06 | Vib Vzw | Spider mite silk proteins |
CN107106727A (en) * | 2014-10-31 | 2017-08-29 | 富士胶片株式会社 | The manufacture method of tubular structure thing, the device for manufacturing tubular structure thing and tubular structure thing |
EP3213776A4 (en) * | 2014-10-31 | 2017-11-22 | FUJIFILM Corporation | Tubular structure, device for producing tubular structure, and method for producing tubular structure |
US10576184B2 (en) | 2014-10-31 | 2020-03-03 | Fujifilm Corporation | Tubular structure, device for manufacturing tubular structure, and method for manufacturing tubular structure |
CN107106727B (en) * | 2014-10-31 | 2021-04-02 | 富士胶片株式会社 | Tubular structure, device for manufacturing tubular structure, and method for manufacturing tubular structure |
JP2016174538A (en) * | 2015-03-18 | 2016-10-06 | 富士フイルム株式会社 | Tubular structure, method for producing cell structure, and method for producing tubular structure |
Also Published As
Publication number | Publication date |
---|---|
EP1202683A1 (en) | 2002-05-08 |
US20010002444A1 (en) | 2001-05-31 |
US20040006383A1 (en) | 2004-01-08 |
AU1631300A (en) | 2001-02-05 |
DE69931401T2 (en) | 2006-12-07 |
EP1202683B1 (en) | 2006-05-17 |
US6616699B2 (en) | 2003-09-09 |
DE69931401D1 (en) | 2006-06-22 |
US7632306B2 (en) | 2009-12-15 |
US6702848B1 (en) | 2004-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6616699B2 (en) | Foam-type vascular prosthesis with well-defined angio-permissive open porosity | |
US7727274B2 (en) | Porous synthetic vascular grafts with oriented ingrowth channels | |
EP1251890B1 (en) | Transmural concentric multilayer ingrowth matrix within well-defined porosity | |
US4661530A (en) | Biocompatible, antithrombogenic materials suitable for reconstructive surgery | |
US5549664A (en) | Artificial blood vessel | |
US6926735B2 (en) | Multi-lumen vascular grafts having improved self-sealing properties | |
EP0230635B1 (en) | Tubular prosthesis having a composite structure | |
US4932964A (en) | Artificial body for a prosthesis | |
US20050222688A1 (en) | Transmural concentric multilayer ingrowth matrix within well-defined porosity | |
EP1669044A2 (en) | Foam-type vascular prosthesis with well-defined angio-permissive open porosity | |
US5462704A (en) | Method for preparing a porous polyurethane vascular graft prosthesis | |
EP0495127B1 (en) | Artificial blood vessel and production thereof | |
JP2553522B2 (en) | Medical tube and method of manufacturing the same | |
WO1993002637A1 (en) | Vascular prosthesis | |
JPS5834137B2 (en) | Composite structure vascular prosthesis and its manufacturing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 16313 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999959063 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999959063 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999959063 Country of ref document: EP |